NR3C2 and hydrops fetalis: When analyzed by the type of pharmacotherapy assessed in RCTs, for HF, 68% of mineralocorticoid receptor antagonist trials and 68% of sodium/glucose cotransporter 2 inhibitor trials included research sites in South Africa compared to 14.3% of renin angiotensin-aldosterone system inhibitors, 9.1% of beta blocker trials, and 0% of diuretic trials (Table 1).